Study design and participants
Tumors, HCC, BCLC
ONCOLOGY, TUMORS
This is a prospective, single-center, real-world study to evaluate the efficacy and safety of ANL with or without S-1 in the first-line treatment of patients with advanced HCC. From February 2019 to August 2021, 54 HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage C (stage I–II, Child‒Pugh A–B, and at least one criteria: PS1-2 or vascular invasion/extrahepatic spread)The main inclusion criteria were as follows: (1) Age ≥ 18 years old, BCLC stage C. (2) Eastern Cooperative Oncology Group (ECOG) physical status score: 0–2, and the estimated survival time was at least 3 months. (3) At least one measurable lesion evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1·1). (4) Hemoglobin ≥ 95 g/L, leukocytes ≥ 4.0 × 10